Retraction Note: Inhibition of hTERT Gene Expression by Silibinin-Loaded PLGA-PEG-Fe₃O₄ in T47D Breast Cancer Cell Line

Abstract

This paper was published in BioImpacts in 2013 (doi: 10.5681/bi.2013.005).1 Based on an email received from a researcher recently, we were informed that this published paper presented some data (i.e., Fig. 3a and 3b) as same as data presented in three other published papers (i.e., doi: 10.1111/Cbdd.12318; doi: 10.1111/Cbdd.12318; and doi: 10.1186/1477-3155-10-46),2-4 which are considered as the ethical misconduct. This issue was brought up with and comprehensively investigated by the editorial team of BioImpacts through comparison of the papers and the within-data. As a result, in accordance with the Committee on Publication Ethics (COPE), the editors decided to retract this paper. The authors were informed and advised on this serious ethical breach. Based on the COPE guidelines on the retraction, BioImpacts considers retracting a publication if: - It has clear evidence that the findings are unreliable, either as a result of misconduct (e.g., data fabrication and/or falsification) or honest error (e.g. miscalculation or experimental error). - The findings have previously been published elsewhere without proper crossreferencing, permission or justification (i.e. cases of redundant publication). As a peer-review multidisciplinary international "Publish Free" and "Access Free" journal, BioImpacts strongly adheres to the "Publication Ethics", and its foremost goal is to preserve the integrity of the scientific reports in the highest standards, therefore, the journal takes all issues of publication misconduct seriously.

Synergistic Anti-proliferative Effects of Metformin and Silibinin Combination on T47D Breast Cancer Cells via hTERT and Cyclin D1 Inhibition

“…Silibinin (SIL), a flavonolignan extracted from Silybum marianum, has been widely investigated for its hepatoprotective, antiinflammatory, antioxidant and anticancer properties (structures shown in ▶Fig. 1a) [10,11]. Furthermore, it has demonstrated considerable efficiency in inhibiting or delaying both tumor initiationand promotion-related incidences in various pre-clinical cancer models such as prostate, colorectal, lung and breast cancer [12,13].…”

Silibinin-loaded magnetic nanoparticles inhibit hTERT gene expression and proliferation of lung cancer cells

“…Magnetic nanoparticles can be used to overcome the issues (Dobson 2006). The magnetic nanoparticles encapsulated with the drug can be arrived to the target position using an external magnetic field and then initiated release of the drug at the proper location (Ebrahimnezhad et al 2013). Therefore, the goal of this study was to synthesize silibinin-loaded PLGA-PEG-Fe 3 O 4 nanoparticles and compared the effects of the pure silibinin and the silibinin-nanomagnetic encapsulated in PLGA-PEG on cell cytotoxicity and hTERT gene expression in A549 lung cancer cell line.…”

An update on applications of nanostructured drug delivery systems in cancer therapy: a review

“…The results from the MTT assay showed that the metabolizing activity of the normal cells was not affected by the PSu; but the drug loaded composites decreased the metabolic activity of the cancerous cells. Thus, the prepared model could potentially be a carrier for anticancer drug, and it could also serve as a postsurgical implant (Ahmadi et al 2014, Ebrahimnezhad et al 2013, Mollazade et al 2013, Pourhassan-Moghaddam et al 2013, Saravanabhavan and Dharmalingam 2013, Zong et al 2015.…”

“…One of the factors causative to poor survival is the lack of ability of a lot of patients to bear a "wide" local cutting out of their tumor, i.e., lobectomy, since elimination of the predictable 25% of whole lung function additional compromises previously restricted pulmonary function. Lesser, i.e., wedge, resections save lung parenchyma but are connected with a two-fold rise in local cancer return as an outcome of the microscopic disease remaining at the surgical resection border (Ebrahimnezhad et al 2013). This is a serious choice since recent two-year survival in patients that grow recurrence drops to 20% (Pourhassan-Moghaddam et al 2013) for instance the mainstream of these patients are not candidates for added surgery, and radiation and/or chemotherapy are largely palliative (Ahmadi et al 2014).…”